BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34569060)

  • 1. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.
    Karanović S; Ardin M; Tang Z; Tomić K; Villar S; Renard C; Venturini E; Lorch AH; Lee DS; Stipančić Ž; Slade N; Vuković Brinar I; Dittrich D; Karlović K; Borovečki F; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
    Int J Cancer; 2022 Jan; 150(2):374-386. PubMed ID: 34569060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
    Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
    Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
    [No Abstract]   [Full Text] [Related]  

  • 3. Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma.
    Boot A; Jiang N; Rozen SG
    Theranostics; 2020; 10(12):5578-5580. PubMed ID: 32373232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
    Dickman KG; Chen CH; Grollman AP; Pu YS
    World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma complicated with aristolochic acid nephropathy after radical nephroureterectomy.
    Shan H; Tian W; Hong Y; Xu B; Wang C; Yu B; Wang X
    BMC Complement Med Ther; 2020 Jun; 20(1):166. PubMed ID: 32493345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive Effects of Arsenic and Aristolochic Acid in Chemical Carcinogenesis of Upper Urinary Tract Urothelium.
    Chen CH; Grollman AP; Huang CY; Shun CT; Sidorenko VS; Hashimoto K; Moriya M; Turesky RJ; Yun BH; Tsai K; Wu S; Chuang PY; Tang CH; Yang WH; Tzai TS; Tsai YS; Dickman KG; Pu YS
    Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):317-325. PubMed ID: 33277322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
    Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
    Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Characterization of Microrna Interference and Aristolochic Acid Intoxication Found in Upper Tract Urothelial Carcinoma in Patients with Balkan Endemic Nephropathy: A Systematic Review of the Current Literature.
    Bašić D; Ignjatović I; Janković Veličković L; Veljković A
    Balkan J Med Genet; 2023 May; 25(2):105-111. PubMed ID: 37265966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.
    Hoang ML; Chen CH; Sidorenko VS; He J; Dickman KG; Yun BH; Moriya M; Niknafs N; Douville C; Karchin R; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
    Sci Transl Med; 2013 Aug; 5(197):197ra102. PubMed ID: 23926200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
    Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
    Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies.
    Kang YC; Chen MH; Lin CY; Lin CY; Chen YT
    Ther Adv Drug Saf; 2021; 12():2042098621997727. PubMed ID: 33815744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular aspects of upper tract urothelial carcinoma.
    Patel N; Arya M; Muneer A; Powles T; Sullivan M; Hines J; Kelly J
    Urol Oncol; 2014 Jan; 32(1):28.e11-20. PubMed ID: 23428541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
    Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
    Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
    Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
    Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
    Audenet F; Isharwal S; Cha EK; Donoghue MTA; Drill EN; Ostrovnaya I; Pietzak EJ; Sfakianos JP; Bagrodia A; Murugan P; Dalbagni G; Donahue TF; Rosenberg JE; Bajorin DF; Arcila ME; Hechtman JF; Berger MF; Taylor BS; Al-Ahmadie H; Iyer G; Bochner BH; Coleman JA; Solit DB
    Clin Cancer Res; 2019 Feb; 25(3):967-976. PubMed ID: 30352907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
    Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
    Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latency period of aristolochic acid-induced upper urinary tract urothelial carcinoma.
    Jhuang JR; Chiu PC; Hsieh TC; Chen CH; Pu YS; Lee WC
    Front Public Health; 2023; 11():1072864. PubMed ID: 36969664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up.
    Lemy A; Wissing KM; Rorive S; Zlotta A; Roumeguere T; Muniz Martinez MC; Decaestecker C; Salmon I; Abramowicz D; Vanherweghem JL; Nortier J
    Am J Kidney Dis; 2008 Mar; 51(3):471-7. PubMed ID: 18295063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid.
    Jelaković B; Dika Ž; Arlt VM; Stiborova M; Pavlović NM; Nikolić J; Colet JM; Vanherweghem JL; Nortier JL
    Semin Nephrol; 2019 May; 39(3):284-296. PubMed ID: 31054628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aristolochic acid-associated urothelial cancer in Taiwan.
    Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
    Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.